{"log_id": 2009003176183236262, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.01503, "average": 0.940233, "min": 0.482251}, "location": {"width": 571, "top": 139, "height": 68, "left": 150}, "words": "事件,发生率大于等于1%的不良反应见卜表"}, {"probability": {"variance": 0.001946, "average": 0.945462, "min": 0.901353}, "location": {"width": 82, "top": 233, "height": 36, "left": 882}, "words": "患者"}, {"probability": {"variance": 0, "average": 0.999684, "min": 0.999457}, "location": {"width": 123, "top": 262, "height": 41, "left": 402}, "words": "不良事件"}, {"probability": {"variance": 0.007612, "average": 0.937315, "min": 0.738395}, "location": {"width": 256, "top": 278, "height": 45, "left": 647}, "words": "厄沙坦/氢氯碑嗪"}, {"probability": {"variance": 0, "average": 0.999354, "min": 0.999067}, "location": {"width": 93, "top": 299, "height": 38, "left": 1047}, "words": "安慰剂"}, {"probability": {"variance": 0.034097, "average": 0.82642, "min": 0.514523}, "location": {"width": 75, "top": 347, "height": 27, "left": 733}, "words": "n=898"}, {"probability": {"variance": 6.4e-05, "average": 0.989862, "min": 0.976675}, "location": {"width": 70, "top": 363, "height": 32, "left": 1056}, "words": "=236"}, {"probability": {"variance": 1.5e-05, "average": 0.996118, "min": 0.99228}, "location": {"width": 66, "top": 386, "height": 36, "left": 425}, "words": "头痛"}, {"probability": {"variance": 0.023151, "average": 0.906937, "min": 0.643447}, "location": {"width": 59, "top": 425, "height": 27, "left": 1060}, "words": "10.2"}, {"probability": {"variance": 5e-06, "average": 0.997526, "min": 0.995251}, "location": {"width": 61, "top": 445, "height": 36, "left": 422}, "words": "头晕"}, {"probability": {"variance": 0.017723, "average": 0.888151, "min": 0.700877}, "location": {"width": 54, "top": 482, "height": 27, "left": 1056}, "words": "3.8"}, {"probability": {"variance": 0, "average": 0.992331, "min": 0.992331}, "location": {"width": 64, "top": 507, "height": 34, "left": 418}, "words": "劳"}, {"probability": {"variance": 0.0002, "average": 0.984936, "min": 0.965338}, "location": {"width": 54, "top": 537, "height": 32, "left": 1053}, "words": "1.7"}, {"probability": {"variance": 0.003964, "average": 0.961638, "min": 0.836841}, "location": {"width": 134, "top": 564, "height": 36, "left": 381}, "words": "恶心/呕吐"}, {"probability": {"variance": 6e-06, "average": 0.998513, "min": 0.994419}, "location": {"width": 123, "top": 621, "height": 38, "left": 384}, "words": "尿液异常"}, {"probability": {"variance": 0, "average": 0.985557, "min": 0.985557}, "location": {"width": 22, "top": 660, "height": 29, "left": 1049}, "words": "0"}, {"probability": {"variance": 0.011947, "average": 0.943489, "min": 0.494299}, "location": {"width": 717, "top": 676, "height": 77, "left": 313}, "words": "半厄贝沙坦/氢氯噻嗪和安慰剂红具有统计学意义的差异"}, {"probability": {"variance": 0.010618, "average": 0.970756, "min": 0.417181}, "location": {"width": 1300, "top": 745, "height": 105, "left": 180}, "words": "其他可能和可能有关或者尚不知是否与治疗有关的、发生率在0.5%-1%之间的临床事件,在合用"}, {"probability": {"variance": 0.015345, "average": 0.934023, "min": 0.521531}, "location": {"width": 1360, "top": 809, "height": 107, "left": 118}, "words": "贝沙坦和氢氯唑嗪治疗组稍高于安慰组,包括:水肿,性功能障碍,腹泻,头晕(体位性):潮红,性欲"}, {"probability": {"variance": 0.01956, "average": 0.942472, "min": 0.367778}, "location": {"width": 1323, "top": 873, "height": 107, "left": 109}, "words": "改变:心动过速,端浮肿。这些事件发生率在厄贝沙坦/氢噻嗪治疗组和安慰剂组没有统计学差异"}, {"probability": {"variance": 0.020996, "average": 0.935996, "min": 0.373174}, "location": {"width": 1305, "top": 944, "height": 102, "left": 166}, "words": "在很少受试者中,厄贝沙坦/氢氯嗪治疗的思老出现与已噻嗪类治疗有关的试验数的变化〔尿"}, {"probability": {"variance": 0.020379, "average": 0.934166, "min": 0.458368}, "location": {"width": 1058, "top": 1005, "height": 93, "left": 102}, "words": "素氮、肌酐和肌酐激酶的增加,血清钾和钠的降低)。这些变化几乎没有临庆意义"}, {"probability": {"variance": 0, "average": 0.937136, "min": 0.937136}, "location": {"width": 100, "top": 1049, "height": 66, "left": 1287}, "words": "大"}, {"probability": {"variance": 0.017382, "average": 0.944669, "min": 0.422783}, "location": {"width": 1300, "top": 1074, "height": 107, "left": 162}, "words": "上市后经验:就如其它血管紧张素Ⅱ受体拮抗剂,有过敏反应(皮疹、荨麻疹、血管性水冲)的报"}, {"probability": {"variance": 0.025131, "average": 0.935497, "min": 0.352114}, "location": {"width": 1348, "top": 1136, "height": 109, "left": 98}, "words": "道。在厄贝沙氧氯治疗上市后监测中,有如下小良反应的报道,也都很见:患弱、腹泻、头晕"}, {"probability": {"variance": 0.006746, "average": 0.975999, "min": 0.511921}, "location": {"width": 1364, "top": 1202, "height": 112, "left": 93}, "words": "消化不良、头痛、高血钾、肌痛、恶心、心动过速、肝功能异常(包括肝炎),肾功能损害包括肾功能"}, {"probability": {"variance": 0.008048, "average": 0.957234, "min": 0.671801}, "location": {"width": 416, "top": 1271, "height": 59, "left": 91}, "words": "衰竭)的个例(见【注意事项】)"}, {"probability": {"variance": 0.001789, "average": 0.984506, "min": 0.780093}, "location": {"width": 1307, "top": 1342, "height": 105, "left": 146}, "words": "有关单个成份的附加信息:尽管只是在临床试验中观察到,先前有关其中单个药物成份报道的其它不"}, {"probability": {"variance": 0.000538, "average": 0.989538, "min": 0.905077}, "location": {"width": 473, "top": 1406, "height": 59, "left": 89}, "words": "良反应可能是本复方的潜在不良反应"}, {"probability": {"variance": 0.007485, "average": 0.931693, "min": 0.809621}, "location": {"width": 125, "top": 1426, "height": 68, "left": 889}, "words": "限公司"}, {"probability": {"variance": 0.006864, "average": 0.965469, "min": 0.588223}, "location": {"width": 1303, "top": 1472, "height": 105, "left": 141}, "words": "厄贝沙坦:除了头痛。骨骼肌损伤和潮红外,不良反应不管是否和药物有关)在厄贝沙坦红和安慰"}, {"probability": {"variance": 0.006887, "average": 0.969328, "min": 0.511753}, "location": {"width": 1364, "top": 1536, "height": 107, "left": 77}, "words": "剂治疗组发生率相同,头痛发生出在安慰剂组明显较高。不同原因和类型的骨骼肌损伤在厄贝沙坦组的发"}, {"probability": {"variance": 0.002213, "average": 0.977845, "min": 0.762651}, "location": {"width": 957, "top": 1600, "height": 93, "left": 77}, "words": "生率明显高于对照组:研究者认为所有报道的骨骼肌损伤与厄贝沙坦无关"}, {"probability": {"variance": 0.00687, "average": 0.955275, "min": 0.719278}, "location": {"width": 1291, "top": 1671, "height": 105, "left": 132}, "words": "潮红在巨贝沙坦红发生率为0.6%,而安慰剂组中没有。潮红的发生与剂量元关,不伴有其他临床事件"}, {"probability": {"variance": 1.2e-05, "average": 0.997632, "min": 0.986297}, "location": {"width": 416, "top": 1733, "height": 61, "left": 75}, "words": "与厄贝沙坦治疗的关系尚不清楚"}, {"probability": {"variance": 0.002171, "average": 0.982725, "min": 0.727697}, "location": {"width": 1310, "top": 1801, "height": 105, "left": 125}, "words": "不管是否与治疗有关,下列其它的不良事件在用厄贝沙坦单独治疗的临床试验中所报道的发生大于"}, {"probability": {"variance": 0.020126, "average": 0.943993, "min": 0.410444}, "location": {"width": 1362, "top": 1865, "height": 109, "left": 66}, "words": "1%,但和安慰剂组没有显著不同:呼吸道感染,骨骼肌痛/肌痛、咳嗽、胸浦、消化良/烧心、腹痛、皮"}, {"probability": {"variance": 0.002466, "average": 0.976334, "min": 0.819525}, "location": {"width": 347, "top": 1936, "height": 52, "left": 61}, "words": "珍、焦虑/紧张、尿道感染"}, {"probability": {"variance": 0.016274, "average": 0.953054, "min": 0.407765}, "location": {"width": 1305, "top": 1998, "height": 105, "left": 118}, "words": "在临庆对照试验中没有出现有临意义的试验室参数变化:尽管在厄贝沙坦治疗组中有床意义的血"}, {"probability": {"variance": 0.006231, "average": 0.95683, "min": 0.670421}, "location": {"width": 1367, "top": 2062, "height": 105, "left": 54}, "words": "浆肌酐激酶升高发生率较高(治疗组1.7米VS安慰剂组0.7%),但这些变化并不属严重不良事件,没有导致"}, {"probability": {"variance": 0.016847, "average": 0.950059, "min": 0.450335}, "location": {"width": 512, "top": 2128, "height": 64, "left": 52}, "words": "治疗中断,也与临床骨骼肛事件不相关"}], "language": 3}